Article
FDA rejects Mallinckrodt's kidney drug over risk-benefit doubts
Rating:
0.0
Views:
127
Likes:
1
Library:
1
The FDA has rejected Mallinckrodt's request for approval of terlipressin in a rare type of progressive kidney failure. Mallinckrodt suffered the setback despite hitting its primary endpoint in phase 3 and winning the backing of an advisory committee in a split decision.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value